Olanzapine May Address AEs From TKIs for Kidney and Other Cancers
Patients treated with tyrosine kinase inhibitors received olanzapine to address adverse effects including nausea/vomiting, anorexia, insomnia, and weight loss.
Enfortumab Vedotin May Be Safe in Ultra-Elderly Patients With Urothelial Carcinoma
Findings also suggested that an up-front dose reduction of enfortumab vedotin may benefit older patients with urothelial carcinoma.
Clinical Practice Gaps Persist in Biomarker Testing for mCRPC Management
With delays in biomarker testing and treatment for metastatic castration-resistant prostate cancer, continued education is needed to address these gaps.
FDA Approves Brentuximab Vedotin Combo for Relapsed/Refractory Large B-Cell Lymphoma
Findings from the ECHELON-3 trial supported the approval of brentuximab vedotin plus lenalidomide and rituximab for relapsed/refractory LBCL.
Oncology Drugs Approved by the FDA in January 2025
January's FDA oncology approvals offer new treatment options for breast cancer, mantle cell lymphoma, and other malignancies.
Telotristat Ethyl Plus Chemo May Stabilize Weight in Metastatic PDAC
Managing weight loss with telotristat ethyl in patients with metastatic pancreatic ductal adenocarcinoma may improve survival, although further research is needed.
Telephone Follow-Ups May Reduce AEs in Locally Advanced ESCC
Phone calls to follow up with patients with locally advanced esophageal squamous cell carcinoma while at home may reduce AEs like stomatitis before the first outpatient clinic visit.
Dose Adjustment May Aid With AE Management for Everolimus-Based Therapy for GEP-NETs
Susumu Hijioka, MD, discussed how a lower dose of everolimus may help address certain adverse events like oral mucositis and hypoglycemia.
Bevacizumab’s Benefit in Colorectal Cancer May Be Limited to 2 Years Post-Administration
The 2-year benefit of bevacizumab in colorectal cancer may explain why survival benefits are seen in studies with two-year, but not longer, follow-ups.
FDA Approves Datopotamab Deruxtecan for Advanced Breast Cancer
Datopotamab deruxtecan-dlnk received approval from the FDA for previously treated unresectable or metastatic, HR-positive, HER2-negative breast cancer.
Investigational Nasal Spray May Improve Symptoms in Cancer Cachexia
Findings from an exploratory 2a study showed improvements in patients with cancer cachexia with PH284 compared with placebo.
New Research Investigating Chemo-Induced Neuropathy in Black Breast Cancer Survivors
An APP’s research is focused on chemo-induced peripheral neuropathy in Black breast cancer survivors and its impact on their long-term quality of life.
Building a Foundation of Trust in Patients With MPNs
Oncology nurses and APPs should prioritize active listening and deeper patient engagement to build trusting, long-term relationships with patients with MPNs.
Exploring Research Opportunities for Oncology Nurses, APPs
An oncology nurse practitioner's transition from private practice to cancer research offers insights for nurses exploring new career paths within oncology.
Ribociclib Combo May Provide Benefit to Certain Breast Cancer Subtypes
Ribociclib plus endocrine therapy shows PFS benefit in luminal B/HER2E breast cancer subtypes compared to chemotherapy, especially with low immune-related gene expression.
Revumenib Combo Yields High Remission Rates in Relapsed/Refractory AML
The combination of revumenib plus decitabine/cedazuridine showed high rates of remission among patients with relapsed/refractory AML with KMT2Ar, NPM1mt, and NUP98r genetic alterations.
Tobacco Smoking Contributes to MDS Molecular Pathogenesis
With a link to specific genetic mutations in myelodysplastic syndromes, tobacco smoking may be associated with disease progression and survival.
Oncology Nurses, APPs Play a ‘Unique Role’ in Sarcoma Treatment
An expert explained the role oncology nurses and advanced practice providers play in caring for patients with sarcoma during treatment.
Supporting Caregivers While Patients Receive Cancer Care
Oncology nurses and APPs play a role in supporting caregivers while the patient they care for receives a diagnosis and cancer treatment.
Understanding the Role of an Oncology Research Nurse
An oncology research nurse balances patient care with rigorous data collection, emphasizing communication and collaboration to advance cancer research.
Amivantamab Plus Chemo Trends Toward Long-Term Benefit in Advanced NSCLC
Amivantamab plus chemotherapy delivered promising OS trends compared with chemotherapy in EGFR-mutant advanced non-small cell lung cancer after disease progression on osimertinib.
Hypofractionated Radiation Noninferior for Lymphedema Prevention in Early Breast Cancer
For patients with early breast cancer, hypofractionated radiation was noninferior to normofractionated radiation regarding lymphedema risk.
Understanding the Mechanism of Action Behind PARP Inhibitors for Prostate Cancer
Michael Lai, ARNP, explained the mechanism of action of PARP inhibitors for the treatment of patients with prostate cancer.
Oncology Drugs Approved by the FDA in August 2024
Throughout August, the FDA approved drugs for the treatment of diseases including non-small cell lung cancer, cutaneous T-cell lymphoma, astrocytoma/oligodendroglioma, and endometrial cancer.
‘Keeping It Human’ When Having Difficult Conversations With Patients Receiving Terminal Cancer Diagnoses
Emotional intelligence becomes a critical tool for oncology nurses to sharpen when having difficult conversations with patients who received a terminal cancer diagnosis.
Tools to Monitor for ICANS During Lymphoma Treatment With Bispecific Antibodies, CAR T-Cell Therapy
The Immune Effector Cell Encephalopathy score and keeping a close eye on patients’ symptoms are critical when monitoring for potential ICANS during lymphoma treatment.
‘Bringing Every Single Resource’ When Caring for Patients Receiving Treatment for Gynecologic Cancers
A multidisciplinary approach to adverse effect management addresses many needs patients with gynecologic cancers may have while undergoing treatment.
Navigating Fertility Preservation Options for Patients Undergoing Cancer Treatment
Although oncology nurses do not relay the initial information around impacted fertility with cancer treatment, they play an important role in guiding patients with any concerns around this topic.
Bringing DEI to Clinical Trial, Cancer Clinics Through Self-Awareness
Applying diversity, equity, and inclusion to cancer clinics can help oncology nurses and APPs make an impact on patient care and research.
Staying Informed on Genetic Targets, Adverse Events of NSCLC Treatments
An expert explained how oncology nurses and APPs should stay informed on the latest genetic mutations that targeted therapies focus in on for non-small cell lung cancer.
Relacorilant/Nab-Paclitaxel Is Convenient, Safe in Ovarian Cancer
Neoadjuvant Nivolumab Regimen Improves OS in Resectable NSCLC
Relacorilant Combo Boosts PFS in Resistant Ovarian Cancer
Nivolumab/Ipilimumab To Be New MSI-H/dMMR mCRC Standard of Care